APA (7th ed.) Citation

Phillips, R., Proudfoot, J., Davicioni, E., Spratt, D., Feng, F., Simko, J., . . . Tran, P. (2023). Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 117(2), S34. https://doi.org/10.1016/j.ijrobp.2023.06.300

Chicago Style (17th ed.) Citation

Phillips, R., et al. "Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer." International Journal of Radiation Oncology, Biology, Physics 117, no. 2 (2023): S34. https://doi.org/10.1016/j.ijrobp.2023.06.300.

MLA (9th ed.) Citation

Phillips, R., et al. "Validation of a Genomic Classifier in the NRG Oncology/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer." International Journal of Radiation Oncology, Biology, Physics, vol. 117, no. 2, 2023, p. S34, https://doi.org/10.1016/j.ijrobp.2023.06.300.